Abstract
Mucopolysaccharidoses (MPS) are a group of genetic disorders due to deficiency of lysosomal enzymes resulting in impaired glycosaminoglycan metabolism. All types of MPS can present with cardiovascular manifestation, although MPS-I, II, and VI seem to have more severe involvement than the other types. Enzyme replacement therapy (ERT) is available for MPS-I, II, and VI. Cardiovascular changes including hypertrophic cardiomyopathy, thickened valvular lesions, and coronary artery lesions often poorly respond to ERT and are well known as leading causes of death in patients with MPS-I. The mechanisms to cause these changes in MPS-I have not been well characterized. Immunohistopathological studies were conducted on the cardiac specimens from a patient with MPS-I who died due to sudden cardiac failure. Phosphorylated Smad2 staining showed hyperactive transforming growth factor-beta (TGF-β) signals in the intimal layer with myointimal proliferation causing stenosis in the coronary arteries as well as in the thickened endocardium and in the myocardial cells. TGF-β is involved in the pathogenesis of cardiovascular diseases including hypertrophic cardiomyopathy and vascular atherosclerosis. The primary mechanisms to cause hyperactive TGF-β signals in MPS-I are unknown. The similar mechanisms leading to hyperactive TGF-β signals may exist in the other types of MPS. The findings of TGF-β hyperactivity in the cardiovascular lesions in a patient with MPS-I may lead to a new therapeutic approach. Further studies are warranted to evaluate the effectiveness of the medications that suppress TGF-β signals, such as losartan, in preventing or improving cardiaovascular lesions in patients with MPS.
Competing interests: None declared
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- MPS:
-
Mucopolysaccharidosis
- TGF-β:
-
Transforming growth factor-beta
References
Brosius FC, Roberts WC (1981) Coronary artery disease in the Hurler syndrome: qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 47(3):649–653
Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156(3):925–938
Hobbs JR, High-Jones K, Barrett AJ et al (1981) Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2(8249):709–712
Karnik SK, Brooke BS, Bayes-Genis A et al (2003) A critical role of elastin signaling in vascular morphogenesis and disease. Development 130(2):411–423
Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118:10–24
Krovetz LJ, Lorincz AE, Schiebler GL (1965) Cardiovascular manifestations of the Hurler syndrome: hemodynamic and angiocardiographic observations in 15 patients. Circulation 31:132–141
Lyons JA, Dickson P, Wall J et al (2011) Arterial pathology in canine mucopolysaccharidosis-1 and response to therapy. Lab Invest 91(5):665–674
Ma X, Tittiger M, Knutsen RH et al (2008) Upregulation of elastase proteins results in aortic dilation in mucopolysaccharidosis I mice. Mol Genet Metab 94(3):298–304
Matalon R, Dorfman A (1968) The structure of acid mucopolysaccharides produced by hurler fibroblasts in tissue culture. Proc Natl Acad Sci USA 60(1):179–185
Pokharel S, Rasoul S, Roks AJM et al (2002) N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40:155–161
Renteria VG, Ferrans VJ, Roberts WC (1976) The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 38(4):487–501
Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-β signaling in vascular fibrosis. Cardiovasc Res 74:196–206
Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90(2):171–180
Venkatesan N, Ouzzine M, Kolb M, Netter P, Ludwig MS (2011) Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of β1,3-glucuronosyltransferase I in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 300(2):L191–L203
Yano S, Moseley K, Pavlova Z (2009) Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis. doi 10.1007/s10545-009-1057-4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Maurizio Scarpa
Appendices
Synopsis
TGF-β hyperactivity is involved in cardiovascular lesions in MPS-I.
References to Electronic Databases
MPS-I (Hurler disease) MIM 607014
Transforming growth factor-beta (TGF-β)
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Yano, S., Li, C., Pavlova, Z. (2012). The Transforming Growth Factor-Beta Signaling Pathway Involvement in Cardiovascular Lesions in Mucopolysaccharidosis-I. In: Brown, G., Morava, E., Peters, V., Gibson, K., Zschocke, J. (eds) JIMD Reports - Case and Research Reports, 2012/4. JIMD Reports, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2012_141
Download citation
DOI: https://doi.org/10.1007/8904_2012_141
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32441-3
Online ISBN: 978-3-642-32442-0
eBook Packages: MedicineMedicine (R0)